Protalix BioTherapeutics, Inc. (PLX) stock
PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 16/3048% below fair value
$2.96−0.17 (-5.43%)
Close on Nov 12, 2026Market cap $238.49MP/E 11.8Yield –
Protalix BioTherapeutics EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Protalix BioTherapeutics's EV/EBITDA was 9.8× on Nov 11, 2026, against 14.0× a year earlier. Over the last 3 years it ranged from 1.8× to 56.1×, with a median of 8.9×.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 9.8× | −12.3 |
| 2025 | Dec 31, 2025 | 22.1× | +14.5 |
| 2024 | Jul 31, 2024 | 7.6× | +0.0 |
| 2023 | Dec 29, 2023 | 7.5× | +5.7 |
| 2021 | Sep 30, 2021 | 1.8× | – |
See a number that looks wrong?